AZD3355 Dose-escalation study in healthy males

Study identifier:D9120C00030

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase 1 single centre single-blind randomised placebo-controlled study to assess the safety, tolerability and pharmacokinetics of oral AZD3355 after administration of single ascending doses and multiple repeated doses in healthy male volunteers

Medical condition

Reflux disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3355, Placebo

Sex

Male

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Sept 2008

Primary Completion Date: 01 Dec 2008

Study Completion Date: 01 Dec 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Gothenburg, Sweden

Arms	Assigned Interventions
Experimental: 1	Drug: AZD3355 capsules, oral, single or twice daily dose Other Name: Lesogaberan
Placebo Comparator: 2	Drug: Placebo To match dosing of AZD3355

"There is no result for the study"

Documents available

CSR-D9120C00030.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Sahlgrenska Universitetssjukhuset

:+46 31 706 5187

Investigators

Principal Investigator

Marianne Hartford

CPU Avd 102, Gröna Stråket 12, Sahlgrenska Universitetssjukhuset, 413 45 Göteborg